Roche announces drug that sets new benchmark for KRAS‑driven lung cancer
read at STAT ↗Positive readoutPositive
Roche has announced a new therapy that it says establishes a new standard of care for patients with KRAS‑driven lung cancer.
The announcement was featured in a STAT+ newsletter, underscoring the potential significance of the drug for the oncology market.
The article does not provide specific trial data or efficacy numbers, but highlights the broader momentum in biotech and targeted cancer treatments.
Analysts view the news as a positive development for both Roche and the KRAS‑targeted therapy space.
source
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Roche drug sets new standard for KRAS-driven lung cancer”
read at STAT ↗423 words · retrieved Jul 2
comments(0)
5-min edit window · permanent after that